Brief Analysis of 2018 Annual Report of EudraVigilance

doi:10.19803/j.1672-8629.2020.01.06

Abstract

Abstract: Objective To analyze the 2018 Annual Report on EudraVigilance so as to provide reference for improving ADR monitoring in China. Methods By literature review, the progress and advantages of the EU pharmacovigilance system in 2018 were analyzed before recommendations were made for ADR monitoring in China. Results EudraVigilance is the central pillar of safety surveillance of European medicines. It has delivered enhanced functionalities that can ensure better support to pharmacovigilance activities and the protection of public health. Conclusion Based on the experience of the EU, it is suggested that we continue to optimize the adverse drug reaction database, explore and research the transparency of surveillance data, and enrich the contents of the annual report in China.

Key words: EU, EudraVigilance, annual report

CLC Number:

R951

DONG Duo, LIU Wei, FAN Yan, PENG Lili, WANG Tao, WANG Dan. Brief Analysis of 2018 Annual Report of EudraVigilance[J]. Chinese Journal of Pharmacovigilance, 2020, 17(1): 26-30.

References

[1] European Medicines Agency.EudraVigilance[EB/OL]. [2019-05-06].https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance.
[2] European Medicines Agency.2018 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission[EB/OL]. (2019-03-21)[2019-05-03]. https://www.ema.europa.eu/en/documents/report/2018-annual-report-eudravigilance-european-parliament-council-commission-reporting-period-1-january_en.pdf.
[3] 王涛,王丹,范燕,等. 欧盟药物警戒数据库功能升级与思考[J]. 中国药物警戒,2018,15(7):411-413.
[4] European Medicines Agency.Change management for the launch of the new EudraVigilance system[EB/OL]. [2019-05-06].https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/change-management-launch-new-eudravigilancesystem.
[5] European Medicines Agency. EudraVigilance Operational Plan Milestones2018 to 2020 [EB/OL].(2018-06-08) [2019-05-03].https://www.ema.europa.eu/documents/other/eudravigilance-operational-plan-milestones-2018-2020_en.pdf.
[6] European Medicines Agency.EudraVigilance system overview[EB/OL]. [2019-05-06] https://www.ema.europa. eu/en/human-regulatory/research-development/pharm-acovigilance/eudravigilance/eudravigilance-system-overview.
[7] European Medicines Agency. EV-M5a EudraVigilance Data Analysis System (EVDAS) training for National Competent Authorities[EB/OL]. (2017-01-06)[2019-05-06]. https://www.ema.europa.eu/en/documents/present-ation/presentation-eudravigilance-data-analysis-system-evdas-training-national-competent-authorities_en.pdf.
[8] European Medicines Agency. List of substances and products subject to worksharing for signal management[EB/OL]. [2019-05-03]. http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500226389.
[9] European Medicines Agency.Signal Management[EB/OL]. [2019-05-06].https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/signal-management.
[10] 中共中央办公厅、国务院办公厅. 关于深化审评审批制度改革鼓励药品医疗器械创新的意见[EB/OL]. (2017-10-08) [2019-05-06]. http://www.gov.cn/xinwen/2017-10/08/content_5230105.htm.
[11] 国家药品监督管理局.关于发布国家药品不良反应监测年度报告(2017年)的公告(2018年第3号)[EB/OL]. (2018-04-13)[2019-05-06]. http://www.nmpa.gov.cn/WS04/CL2138/227761.html.
[12] 中国国家药品监督管理局.中国国家药品监督管理局当选为国际人用药品注册技术协调会管理委员会成员[EB/OL]. (2018-06-07)[2019-05-06]. http://www.nmpa.gov.cn/WS04/CL2056/228304.html.
[13] 国家药品监督管理局. 总局关于适用国际人用药品注册技术协调会二级指导原则的公告(2018年第10号)[EB/OL]. (2018-01-25)[2019-05-06], http://www.nmpa.gov.cn/WS04/CL2138/300493.html.
[14] Uppsala Monitoring Center. VigiAcess[EB/OL]. [2019-05-03]. http://www.vigiaccess.org/
[15] U.S Food and Drug Administration.FARES Public Dash-board[EB/OL]. [2019-05-03]. https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/7a47a-261-d58b-4203-a8aa-6d3021737452/state/analysis.